Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
About this item
Full title
Author / Creator
Kwatra, Shawn G. , Yosipovitch, Gil , Legat, Franz J. , Reich, Adam , Paul, Carle , Simon, Dagmar , Naldi, Luigi , Lynde, Charles , De Bruin-Weller, Marjolein S. , Nahm, Walter K. , Sauder, Maxwell , Gharib, Rola , Barbarot, Sebastien , Szepietowski, Jacek C. , Conrad, Curdin , Fleischer, Alan , Laquer, Vivian T. , Misery, Laurent , Serra-Baldrich, Esther , Lapeere, Hilde , Ahmad, Faiz , Jabbar Lopez, Zarif K. , Piketty, Christophe , Ständer, Sonja and OLYMPIA 2 Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.
In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodular...
Alternative Titles
Full title
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Authors, Artists and Contributors
Author / Creator
Yosipovitch, Gil
Legat, Franz J.
Reich, Adam
Paul, Carle
Simon, Dagmar
Naldi, Luigi
Lynde, Charles
De Bruin-Weller, Marjolein S.
Nahm, Walter K.
Sauder, Maxwell
Gharib, Rola
Barbarot, Sebastien
Szepietowski, Jacek C.
Conrad, Curdin
Fleischer, Alan
Laquer, Vivian T.
Misery, Laurent
Serra-Baldrich, Esther
Lapeere, Hilde
Ahmad, Faiz
Jabbar Lopez, Zarif K.
Piketty, Christophe
Ständer, Sonja
OLYMPIA 2 Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_04338757v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04338757v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2301333
